FI970351A - Identifiering av en human cytomegalovirusgenregion som är involverad i minskningen av MHC klass I-tungkedsexpression - Google Patents
Identifiering av en human cytomegalovirusgenregion som är involverad i minskningen av MHC klass I-tungkedsexpression Download PDFInfo
- Publication number
- FI970351A FI970351A FI970351A FI970351A FI970351A FI 970351 A FI970351 A FI 970351A FI 970351 A FI970351 A FI 970351A FI 970351 A FI970351 A FI 970351A FI 970351 A FI970351 A FI 970351A
- Authority
- FI
- Finland
- Prior art keywords
- identification
- reduction
- heavy chain
- mhc class
- human cytomegalovirus
- Prior art date
Links
- 241000701024 Human betaherpesvirus 5 Species 0.000 title 1
- 102000043129 MHC class I family Human genes 0.000 title 1
- 108091054437 MHC class I family Proteins 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
- C07K14/04—Varicella-zoster virus
- C07K14/045—Cytomegalovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16141—Use of virus, viral particle or viral elements as a vector
- C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16161—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16161—Methods of inactivation or attenuation
- C12N2710/16162—Methods of inactivation or attenuation by genetic engineering
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/282,696 US5846806A (en) | 1994-07-29 | 1994-07-29 | Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression |
PCT/US1995/009607 WO1996004383A1 (en) | 1994-07-29 | 1995-07-28 | Identification of a human cytomegalovirus gene region involved in down-regulation of mhc class i heavy chain expression |
Publications (2)
Publication Number | Publication Date |
---|---|
FI970351A0 FI970351A0 (sv) | 1997-01-28 |
FI970351A true FI970351A (sv) | 1997-01-28 |
Family
ID=23082718
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI970352A FI970352A (sv) | 1994-07-29 | 1997-01-28 | Identifiering av en human cytomegalovirusgen som är involverad i minskningen av MHC klass I -tungkedsexpression |
FI970351A FI970351A (sv) | 1994-07-29 | 1997-01-28 | Identifiering av en human cytomegalovirusgenregion som är involverad i minskningen av MHC klass I-tungkedsexpression |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI970352A FI970352A (sv) | 1994-07-29 | 1997-01-28 | Identifiering av en human cytomegalovirusgen som är involverad i minskningen av MHC klass I -tungkedsexpression |
Country Status (11)
Country | Link |
---|---|
US (6) | US5846806A (sv) |
EP (2) | EP0775209A1 (sv) |
JP (2) | JP4036469B2 (sv) |
KR (2) | KR970704883A (sv) |
AU (2) | AU709552B2 (sv) |
CA (3) | CA2195668C (sv) |
FI (2) | FI970352A (sv) |
MX (1) | MX9700676A (sv) |
NO (2) | NO970369L (sv) |
NZ (2) | NZ290718A (sv) |
WO (2) | WO1996004383A1 (sv) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997032605A1 (en) * | 1996-03-08 | 1997-09-12 | Massachusetts Institute Of Technology | Cytomegalovirus nucleic acids encoding proteins having normal or altered class i mhc binding and treatment of diseases |
AU730351B2 (en) * | 1996-07-31 | 2001-03-08 | Ortho-Mcneil Pharmaceutical, Inc. | Identification of human cytomegalovirus genes involved in down-regulation of MHC class I heavy chain expression |
WO1998031813A1 (de) * | 1997-01-17 | 1998-07-23 | Roche Diagnostics Gmbh | Inhibitor für die präsentation von antigenen durch mhc-klasse i moleküle |
WO1998047914A2 (de) * | 1997-04-18 | 1998-10-29 | Roche Diagnostics Gmbh | Us6 gen aus dem humanen cytomegalovirus (hcmv) |
JP2002508976A (ja) * | 1998-01-14 | 2002-03-26 | ヒューマン ジーン セラピー リサーチ インスティテュート | 遺伝子療法において使用するための、免疫原性が低下したヌクレオチド発現システム |
US6100008A (en) * | 1998-09-14 | 2000-08-08 | Ppg Industries Ohio, Inc. | Positive photoresist with improved contrast ratio and photospeed |
WO2000046361A1 (en) * | 1999-02-02 | 2000-08-10 | Oregon Health Sciences University | Inhibition of the mhc class ii antigen presentation pathway and presentation to cd4+ cells |
AU2001288682A1 (en) * | 2000-08-30 | 2002-03-13 | Chemocentryx, Inc. | Inhibition of cmv infection and dissemination |
US6740324B2 (en) * | 2001-02-02 | 2004-05-25 | Chemocentryx, Inc. | Methods and compositions useful for stimulating an immune response |
US20030118568A1 (en) * | 2001-12-18 | 2003-06-26 | Board Of Trustees Of The University Of Arkansas | Viral stealth technology to prevent T cell-mediated rejection of xenografts |
US20040228842A1 (en) * | 2003-02-27 | 2004-11-18 | Shan Lu | Compositions and methods for cytomegalovirus treatment |
KR20050093003A (ko) * | 2004-03-17 | 2005-09-23 | 이재본 | 직류형 마이크로 터빈 발전기 |
EP2114991A1 (en) | 2007-02-07 | 2009-11-11 | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. | Recombinant antigens of human cytomegalovirus (hcmv) |
CA2705461A1 (en) * | 2007-11-12 | 2009-06-11 | The Trustees Of The University Of Pennsylvania | Vaccines against multiple subtypes of influenza virus |
ES2625406T3 (es) | 2010-03-25 | 2017-07-19 | Oregon Health & Science University | Glicoproteínas de CMV y vectores recombinantes |
LT2569436T (lt) | 2010-05-14 | 2018-03-12 | Oregon Health & Science University | Rekombinantiniai žcmv ir hcmv vektoriai ir jų panaudojimas |
SI2691530T1 (en) | 2011-06-10 | 2018-08-31 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
CA2904001C (en) | 2013-03-05 | 2021-07-13 | Oregon Health & Science University | Cytomegalovirus vectors enabling control of t cell targeting |
MA39818A (fr) | 2014-03-30 | 2017-02-08 | Benevir Biopharm Inc | Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques |
WO2016011293A1 (en) | 2014-07-16 | 2016-01-21 | Oregon Health & Science University | Human cytomegalovirus comprising exogenous antigens |
CN108064304A (zh) | 2015-02-10 | 2018-05-22 | 俄勒冈健康与科学大学 | 可用于产生非典型cd8+ t细胞应答的方法和组合物 |
EP3377636A4 (en) | 2015-11-20 | 2019-11-06 | Oregon Health & Science University | CMV VECTORS WITH MIKRORNA DETECTION ELEMENTS |
US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
CN109843321A (zh) | 2016-06-22 | 2019-06-04 | 国际艾滋病疫苗行动组织公司 | 作为结核病疫苗的重组巨细胞病毒载体 |
CN110036112B (zh) | 2016-10-18 | 2024-05-10 | 俄勒冈健康与科学大学 | 引发受主要组织相容性复合体e分子限制的t细胞的巨细胞病毒载体 |
US11638749B2 (en) | 2017-10-17 | 2023-05-02 | International Aids Vaccine Initiative, Inc. | Tuberculosis antigen cassettes |
US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
TW202413391A (zh) | 2020-06-21 | 2024-04-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白B(gB)多肽 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4058598A (en) * | 1974-10-18 | 1977-11-15 | Harold Stern | Cytomegalovirus attenuation method and vaccine |
US4689225A (en) * | 1984-11-02 | 1987-08-25 | Institut Merieux | Vaccine for cytomegalovirus |
US4877612A (en) * | 1985-05-20 | 1989-10-31 | Frank M. Berger | Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process |
US4877737A (en) * | 1985-09-06 | 1989-10-31 | Prutech Research And Development Partnership | Attenuated pseudorabies virus which has a deletion in at least a portion of a repeat sequence and vaccine containing same |
US5273876A (en) * | 1987-06-26 | 1993-12-28 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene |
ATE118822T1 (de) * | 1987-06-26 | 1995-03-15 | Syntro Corp | Rekombinanter, fremde gene enthaltender menschlicher cytomegalovirus und seine verwendung. |
AU3550489A (en) * | 1988-05-09 | 1989-11-29 | Children's Hospital Incorporated, The | Vectors encoding hcmv glycoprotein and expression products |
SG49046A1 (en) * | 1991-07-05 | 1998-05-18 | American Cyanamid Co | Method for identifying non-essential genes of the human cytomegalovirus genome and for screening for inhibitors of human cytomegaloverirus |
-
1994
- 1994-07-29 US US08/282,696 patent/US5846806A/en not_active Expired - Fee Related
-
1995
- 1995-06-02 US US08/459,586 patent/US5720957A/en not_active Expired - Fee Related
- 1995-06-02 US US08/458,544 patent/US5753476A/en not_active Expired - Fee Related
- 1995-07-28 JP JP50665896A patent/JP4036469B2/ja not_active Expired - Fee Related
- 1995-07-28 CA CA002195668A patent/CA2195668C/en not_active Expired - Fee Related
- 1995-07-28 AU AU31535/95A patent/AU709552B2/en not_active Ceased
- 1995-07-28 EP EP95927533A patent/EP0775209A1/en not_active Withdrawn
- 1995-07-28 WO PCT/US1995/009607 patent/WO1996004383A1/en not_active Application Discontinuation
- 1995-07-28 NZ NZ290718A patent/NZ290718A/xx unknown
- 1995-07-31 CA CA002196207A patent/CA2196207C/en not_active Expired - Fee Related
- 1995-07-31 CA CA002328638A patent/CA2328638A1/en not_active Abandoned
- 1995-07-31 MX MX9700676A patent/MX9700676A/es unknown
- 1995-07-31 NZ NZ291571A patent/NZ291571A/xx unknown
- 1995-07-31 US US08/509,214 patent/US5843458A/en not_active Expired - Fee Related
- 1995-07-31 WO PCT/US1995/009799 patent/WO1996004384A1/en not_active Application Discontinuation
- 1995-07-31 JP JP8506737A patent/JPH10506268A/ja not_active Ceased
- 1995-07-31 AU AU32745/95A patent/AU708983B2/en not_active Ceased
- 1995-07-31 EP EP95929364A patent/EP0772681A1/en not_active Withdrawn
-
1997
- 1997-01-28 NO NO970369A patent/NO970369L/no not_active Application Discontinuation
- 1997-01-28 FI FI970352A patent/FI970352A/sv unknown
- 1997-01-28 FI FI970351A patent/FI970351A/sv unknown
- 1997-01-28 NO NO970370A patent/NO970370L/no not_active Application Discontinuation
- 1997-01-29 KR KR1019970700611A patent/KR970704883A/ko not_active Application Discontinuation
- 1997-01-29 KR KR1019970700612A patent/KR970704884A/ko not_active Application Discontinuation
- 1997-10-07 US US08/946,598 patent/US5906935A/en not_active Expired - Fee Related
-
1998
- 1998-03-16 US US09/039,802 patent/US5908780A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2195668A1 (en) | 1996-02-15 |
WO1996004383A1 (en) | 1996-02-15 |
AU3274595A (en) | 1996-03-04 |
NO970370D0 (no) | 1997-01-28 |
KR970704883A (ko) | 1997-09-06 |
KR970704884A (ko) | 1997-09-06 |
CA2195668C (en) | 2004-09-21 |
AU708983B2 (en) | 1999-08-19 |
NO970370L (no) | 1997-03-24 |
CA2328638A1 (en) | 1996-02-15 |
US5753476A (en) | 1998-05-19 |
CA2196207C (en) | 2002-04-30 |
US5843458A (en) | 1998-12-01 |
MX9700710A (es) | 1997-09-30 |
EP0772681A1 (en) | 1997-05-14 |
NO970369L (no) | 1997-03-21 |
US5846806A (en) | 1998-12-08 |
FI970351A0 (sv) | 1997-01-28 |
CA2196207A1 (en) | 1996-02-15 |
NZ291571A (en) | 1999-01-28 |
US5908780A (en) | 1999-06-01 |
JPH10506268A (ja) | 1998-06-23 |
AU709552B2 (en) | 1999-09-02 |
NZ290718A (en) | 1999-03-29 |
US5720957A (en) | 1998-02-24 |
FI970352A0 (sv) | 1997-01-28 |
JPH10503378A (ja) | 1998-03-31 |
WO1996004384A1 (en) | 1996-02-15 |
US5906935A (en) | 1999-05-25 |
AU3153595A (en) | 1996-03-04 |
EP0775209A1 (en) | 1997-05-28 |
NO970369D0 (no) | 1997-01-28 |
FI970352A (sv) | 1997-01-28 |
MX9700676A (es) | 1997-04-30 |
JP4036469B2 (ja) | 2008-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI970351A0 (sv) | Identifiering av en human cytomegalovirusgenregion som är involverad i minskningen av MHC klass I-tungkedsexpression | |
DE69712278D1 (de) | Verdicktes Körperpflegemittel | |
DE69524813D1 (de) | Verdickte kosmetische Mittel | |
DE69600048D1 (de) | Kosmetisches Haarwaschmittel und dessen Verwendung | |
DE19581884T1 (de) | Verschachtelungs- und sequentieller Zähler | |
DE69808253D1 (de) | Zerlegbarer behälter | |
AU1429397A (en) | Labeled vitamin d compounds and the use thereof | |
DE69831489D1 (de) | Körperpflegemittel | |
DE59610836D1 (de) | Mittel gegen parasitäre protozoen | |
DE69404505D1 (de) | Auslass-Verschluss | |
DE19581885T1 (de) | Verschachtelungs- und sequentieller Zähler | |
DE59506998D1 (de) | Kosmetische mittel | |
KR960032824U (ko) | 안전콘센트 | |
KR960029766U (ko) | 안전용 콘센트 | |
DE59509748D1 (de) | Radikalisch polymerisierbare Zubereitungen und ihre Verwendung | |
KR970025956U (ko) | 승강식 안전 콘센트 | |
KR950023981U (ko) | 안전 콘센트 | |
KR960029761U (ko) | 안전콘센트 | |
KR970004155A (ko) | 안전 콘센트 | |
KR960035662U (ko) | 안전 콘센트 | |
KR970015399U (ko) | 전원차단용 콘센트 | |
KR960032818U (ko) | 안전콘센트 | |
KR960032816U (ko) | 안전콘센트 | |
KR960032819U (ko) | 안전콘센트 | |
KR970003343U (ko) | 안전콘센트 |